Dipeptide Peptidase 4 Inhibitor Market Forecasts to 2030 – Global Analysis By Drug Type (Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin and Other Drug Types), Application (Hospitals, Clinics and Other Applicati

Dipeptide Peptidase 4 Inhibitor Market Forecasts to 2030 – Global Analysis By Drug Type (Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin and Other Drug Types), Application (Hospitals, Clinics and Other Applications) and by Geography

According to Stratistics MRC, the Global Dipeptide Peptidase 4 Inhibitor Market is accounted for $11.3 billion in 2023 and is expected to reach $15.69 billion by 2030 growing at a CAGR of 4.8% during the forecast period. A class of drugs called dipeptidyl peptidase 4 (DPP-4) inhibitors is used to treat type 2 diabetes. The enzyme DPP-4 is responsible for the breakdown of incretin hormones, which are essential for controlling blood sugar levels. These drugs work by blocking DPP-4, which increases the effect of incretins, specifically glucagon-like peptide-1 (GLP-1), which raises insulin secretion and lowers glucagon production. As a result, blood sugar levels are lowered, and glucose regulation is enhanced.

According to the American Diabetes Association, Dipeptidyl Peptidase 4 (DPP-4) Inhibitors represent a valuable class of medications for the management of type 2 diabetes. These inhibitors, by targeting the DPP-4 enzyme, enhance the effectiveness of incretin hormones, contributing to improved blood sugar control.

Market Dynamics:

Driver:

Rising incidence of diabetes

The market for dipeptidyl peptidase 4 (DPP-4) inhibitors is significantly driven by the ongoing worldwide rise in the prevalence of diabetes. By 2030, there will be 537 million people worldwide estimated to have diabetes, creating a growing need for efficient diabetes medications. Furthermore, DPP-4 inhibitors meet this need by providing a workable treatment option for individuals with type 2 diabetes, thereby contributing to the overall growth of the market.

Restraint:

Potential safety issues

Dipeptidyl Peptidase 4 (DPP-4) inhibitors have raised some safety concerns despite having a generally good safety profile. Patients and healthcare professionals may be reluctant to take certain medications due to reports of uncommon but dangerous side effects, such as pancreatitis and joint pain. Moreover, it is imperative to acknowledge and comprehend these possible hazards in order to guarantee the sustained credibility and approval of DPP-4 inhibitors within the industry.

Opportunity:

Extending treatment guidelines and indications

Potential opportunities for Dipeptidyl Peptidase 4 (DPP-4) inhibitors include the inclusion of these drugs in updated treatment guidelines and the possible expansion of their indications. Additionally, expansion of indications and new paths for market growth and adoption may result from ongoing research and clinical trials examining the advantages of DPP-4 inhibitors in particular patient populations or in conjunction with other therapies.

Threat:

Price pressures and generic erosion

When the patents for branded drugs expire, the DPP-4 inhibitor market faces challenges from the threat of generic erosion. Price pressure may increase when generic alternatives, which are usually provided at a lower cost, are available. Furthermore, pharmaceutical companies that produce the branded versions may see a decrease in profitability as a result of this phenomenon, which could have an effect on their investment in R&D and marketing resources.

Covid-19 Impact

The Dipeptidyl Peptidase 4 (DPP-4) inhibitor market has been impacted by the COVID-19 pandemic in many ways. Prescription patterns and patient adherence have been impacted by changes in patient priorities, disruptions in healthcare systems, and financial difficulties. The adoption of telehealth has increased dramatically, impacting the conventional dynamics of patient interactions and pharmaceutical sales. Additionally, the market has fluctuated even though the demand for anti-diabetic drugs has remained strong. This highlights the need for pharmaceutical companies to remain innovative and flexible in order to deal with the ongoing effects of the global health crisis.

The Sitagliptin segment is expected to be the largest during the forecast period

It is projected that the sitagliptin segment will have the largest market share. Sitagliptin, sold under several brand names, is a commonly prescribed drug for the treatment of type 2 diabetes. It works by inhibiting the DPP-4 enzyme, which significantly lowers blood sugar levels. Its favorable safety profile, ease of oral administration, and proven ability to improve glycemic control are the reasons for its popularity. Moreover, sitagliptin has a strong hold in the DPP-4 inhibitor market thanks to its broad usage and wealth of clinical experience.

The Clinics segment is expected to have the highest CAGR during the forecast period

The market's highest CAGR has been seen in the clinic segment. This pattern points to a change in patient preferences and the ways that healthcare is delivered. Clinics are becoming more and more popular for offering a variety of medical services, such as regular check-ups, preventive care, and specialized treatments. They are distinguished by their more easily accessible and convenient healthcare services. The rapid expansion of clinics has been driven by the growing need for outpatient care as well as the growing emphasis on individualized and community-based healthcare. Additionally, clinics are growing more rapidly because of the efficiency, shorter wait times, and individualized care they provide to their patients.

Region with largest share:

North America holds the largest market share for dipeptide peptidase 4 (DPP-4) inhibitors. A class of drugs called DPP-4 inhibitors is prescribed to treat type 2 diabetes. For a number of reasons, North America commands a sizable portion of the DPP-4 inhibitor market. First off, the need for efficient treatment options is fueled by the high rate of type 2 diabetes in the area. The majority of Americans with diabetes, approximately 34 million, have type-2 diabetes, according to the Centers for Disease Control and Prevention (CDC). Furthermore, North America also boasts a well-established healthcare infrastructure, which includes pharmaceutical companies, cutting-edge medical research facilities, and regulatory frameworks.

Region with highest CAGR:

The dipeptide peptidase 4 (DPP-4) inhibitor market is anticipated to grow at the highest CAGR in the Asia-Pacific region. A class of drugs called DPP-4 inhibitors is prescribed to treat type 2 diabetes. The nations of China, India, Japan, Australia, and other countries are included in the Asia-Pacific region. The Asia-Pacific DPP-4 inhibitor market is growing at a rapid rate due to a number of factors. There are many people in the area who are either at risk of developing type-2 diabetes or who have already been diagnosed with the disease, and the population is growing quickly. Moreover, a sizeable market is created for diabetes drugs, such as DPP-4 inhibitors, by this demographic trend.

Key players in the market

Some of the key players in Dipeptide Peptidase 4 Inhibitor market include Merck, Boehringer Ingelheim, Novartis, AstraZeneca, GlaxoSmithKline, Eli Lilly and Company, Pfizer, Sanofi, Bristol-Myers Squibb and Takeda Pharmaceuticals.

Key Developments:

In February 2024, Novartis announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based, global biopharmaceutical company developing innovative medicines in oncology. According to a press statement, the acquisition, which is subject to customary closing conditions, including a minimum acceptance threshold of 65 percent of outstanding shares tendered in the takeover offer and regulatory approvals.

In February 2024, Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile.

In November 2023, Boehringer Ingelheim and IBM announced an agreement that will enable Boehringer to use IBM’s foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics. Boehringer will be using an IBM-developed, pre-trained AI model that will be further fine-tuned on additional Boehringer proprietary data.

Drug Types Covered:
• Sitagliptin
• Vildagliptin
• Saxagliptin
• Linagliptin
• Gemigliptin
• Anagliptin
• Teneligliptin
• Other Drug Types

Applications Covered:
• Hospitals
• Clinics
• Other Applications

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances